480 related articles for article (PubMed ID: 31411986)
1. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Joseph JS; Lam V; Patel MI
Eur Urol Oncol; 2019 Sep; 2(5):551-561. PubMed ID: 31411986
[TBL] [Abstract][Full Text] [Related]
2. Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.
Wu C; Chen W; Huang X; Lin R; Wu J; Zhang X
Clin Genitourin Cancer; 2018 Dec; 16(6):e1243-e1250. PubMed ID: 30146230
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Anticancer Res; 2017 Jul; 37(7):3667-3671. PubMed ID: 28668858
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures.
Poon Y; Pechlivanoglou P; Alibhai SMH; Naimark D; Hoch JS; Papadimitropoulos E; Hogan ME; Krahn M
BJU Int; 2018 Jan; 121(1):17-28. PubMed ID: 28921820
[TBL] [Abstract][Full Text] [Related]
5. Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Tomlinson GA; Winquist E
Ann Intern Med; 2017 Sep; 167(5):341-350. PubMed ID: 28785760
[TBL] [Abstract][Full Text] [Related]
6. A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study.
Yoshida T; Kinoshita H; Taniguchi H; Yanishi M; Sugi M; Matsuda T
Osteoporos Int; 2020 Jul; 31(7):1251-1259. PubMed ID: 31993719
[TBL] [Abstract][Full Text] [Related]
7. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
Alibhai SM; Mohamedali HZ; Gulamhusein H; Panju AH; Breunis H; Timilshina N; Fleshner N; Krahn MD; Naglie G; Tannock IF; Tomlinson G; Warde P; Duff Canning S; Cheung AM
Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
[TBL] [Abstract][Full Text] [Related]
8. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
9. The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.
Nicolopoulos K; Moshi MR; Stringer D; Ma N; Jenal M; Vreugdenburg T
Arch Osteoporos; 2023 Jan; 18(1):18. PubMed ID: 36624318
[TBL] [Abstract][Full Text] [Related]
10. Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: a prospective open-label study.
Rodrigues P; Meler A; Hering F
Urol Int; 2010; 85(2):180-5. PubMed ID: 20628233
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Osteoporosis in Men on Androgen Deprivation Therapy in Japan.
Nishimoto H; Inui A; Mifune Y; Yamaura K; Bando Y; Okamura Y; Hara T; Terakawa T; Kuroda R
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674197
[No Abstract] [Full Text] [Related]
12. Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.
Alibhai SMH; Breunis H; Timilshina N; Hamidi MS; Cheung AM; Tomlinson GA; Manokumar T; Samadi O; Sandoval J; Durbano S; Warde P; Jones JM
Cancer; 2018 Mar; 124(6):1132-1140. PubMed ID: 29211305
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis.
Ding H; Yang L; Du W; Teng Y; Fu SJ; Tao Y; Lu JZ; Wang ZP
Asian Pac J Cancer Prev; 2013; 14(5):3337-43. PubMed ID: 23803126
[TBL] [Abstract][Full Text] [Related]
14. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
Magno C; Anastasi G; Morabito N; Gaudio A; Maisano D; Franchina F; Galì A; Frisina N; Melloni D
Eur Urol; 2005 May; 47(5):575-80; discussion 580-1. PubMed ID: 15826746
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
16. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
[TBL] [Abstract][Full Text] [Related]
17. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
Kudlacek S; Puntus T
Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
Smith MR
Drugs Aging; 2003; 20(3):175-83. PubMed ID: 12578398
[TBL] [Abstract][Full Text] [Related]
19. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
Schulman C; Irani J; Aapro M
BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
[TBL] [Abstract][Full Text] [Related]
20. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
